#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Dermatitis atopic Dementia Alzheimer's type Asthma Breast cancer metastatic Type 2 diabetes mellitus Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Thalassaemia beta HER2 gene amplification Eosinophilic granulomatosis with polyangiitis Bronchopulmonary aspergillosis Loeys-Dietz syndrome Optic glioma Monogenic diabetes Synovial sarcoma metastatic Glioblastoma multiforme Angelman's syndrome Polyneuropathy Alveolar proteinosis Craniocerebral injury Postprandial hypoglycaemia Pancreatic carcinoma metastatic More trials…

    Learn about Rare Diseases

    Pleural mesothelioma malignant – Basic Information Ocular melanoma Breast angiosarcoma metastatic – Basic Information Synovial sarcoma – Trials in Disease Pulmonary sarcoidosis – Diagnostics Ewing’s sarcoma – Treatment Factor IX deficiency Osteosarcoma metastatic – Trials in Disease Sjogren’s syndrome Glomerulonephritis membranoproliferative – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Benzathine Benzylpenicillin Befiradol (18F) LY4170156 Phleum Pratense Pollen Extract Onasemnogene Abeparvovec Lonapegsomatropin Zagociguat Ethanol, Anhydrous Febuxostat Peginterferon Beta-1A Io103 Acetate Tucidinostat Tradipitant Daridorexant Raludotatug Deruxtecan Mogamulizumab Dordaviprone Iomeprol Daunorubicin Ifinatamab Deruxtecan More therapies…

    Learn about Your Condition

    Deafness neurosensory Undifferentiated sarcoma Thermal burn Arteriovenous graft thrombosis Carotid artery occlusion Alveolar rhabdomyosarcoma Choroidal neovascularisation Progressive multiple sclerosis Vulvovaginal candidiasis Hip fracture Plasma cell myeloma refractory Rhinitis allergic Pleural mesothelioma malignant Retinal neovascularisation Acute kidney injury More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. Centre Oscar Lambret

Centre Oscar Lambret

3 Rue Frederic Combemale, Lille, 59000, France

Want to learn more about this study or check if you can participate? Contact us.

  • Study of xaluritamig plus abiraterone for men with metastatic castration-resistant prostate cancer who have not received chemotherapy

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Cabazitaxel
    • Xaluritamig
    • Siltuximab
    Austria Belgium France Germany Greece Italy +3

  • Testing sacituzumab govitecan and trastuzumab deruxtecan in alternating pattern for patients with HER2-low triple-negative breast cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Triple negative breast cancer
    Investigated Drugs:
    • Sacituzumab Govitecan
    • Trastuzumab Deruxtecan
    France

  • Study of Izalontamab Brengitecan Compared to Standard Chemotherapy in Untreated Triple-negative or ER-low, HER2-negative Breast Cancer Patients Not Eligible for Anti-PD1/PD-L1 Treatment

    Recruiting

    4 1 1 1
    Investigated Drugs:
    • Capecitabine
    • Carboplatin
    • Gemcitabine
    Austria France Germany Greece Italy Poland +4

  • Study of Trastuzumab Deruxtecan Blood Levels in Normal Weight and Overweight Patients with Metastatic Breast Cancer

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Breast cancer metastatic
    Investigated Drugs:
    • Trastuzumab Deruxtecan
    France

  • Study of Tarlatamab and Temozolomide combination treatment in adolescents and adults with high grade brain tumors

    Recruiting

    1 1 1 1
    Investigated Diseases:
    • Brain neoplasm
    Investigated Drugs:
    • Tarlatamab
    • Temozolomide
    France

  • Study of ficerafusp alfa and pembrolizumab as first treatment for patients with PD-L1-positive recurrent or metastatic head and neck cancer

    Recruiting

    4 1 1
    Investigated Drugs:
    • Pembrolizumab
    Austria Belgium Czechia France Germany Greece +5

  • Study of personalized treatment using drug combination therapy for young women with early stage hormone receptor-positive breast cancer based on gene expression testing

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hormone receptor positive HER2 negative breast cancer
    Investigated Drugs:
    • Epirubicin
    • Goserelin
    • Triptorelin
    Belgium France Greece Ireland Italy Poland +1

  • Study of ivonescimab with chemotherapy combination for first and second-line treatment in patients with advanced or metastatic gastric and gastroesophageal cancer

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastric cancer stage IV
    • Oesophageal carcinoma
    Investigated Drugs:
    • Calcium Levofolinate
    • Ivonescimab
    • Fluorouracil
    France

  • Study of mirvetuximab soravtansine dosing schedules for patients with platinum-resistant advanced ovarian, peritoneal, or fallopian tube cancer with high folate receptor expression

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Mirvetuximab Soravtansine
    • Prednisolone Acetate
    Belgium France Poland Spain

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour of the lung
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Dacarbazine
    • Tarlatamab
    • Irinotecan Hydrochloride Trihydrate
    France
Previous Page
1 2 3 4 5 … 26
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!